Sanofi reports Q2 business EPS EUR 1.74, up 8.1% at CER

Business EPS was EUR 1.74, up 0.6% on a reported basis and 8.1% at CER, while IFRS EPS was EUR 1.15, up 22.3%. Reports Q1 IFRS net sales EUR 9.97B, up 3.3% at CER. Paul Hudson, Sanofi CEO commented: “We have delivered yet another quarter of growth, with Specialty Care and Vaccines as the main drivers. As we move into the second half our Play to Win strategy, we are particularly enthusiastic about the strong flow of positive R&D data readouts and regulatory achievements of this second quarter, highlighting the significant growth potential of our innovative pipeline assets. With the FDA approval of Beyfortus for the prevention of RSV in all infants in July, the landmark Phase 3 data in COPD with Dupixent, and the important clinical milestones with amlitelimab and frexalimab which support our decision to initiate pivotal trials, we expect to add multiple innovative medicines to our existing growth drivers over the coming years. As we enter the second half of 2023, we are executing on our new launches and we are encouraged by the early launch indicators of ALTUVIIIO and TZIELD, while navigating the anticipated impact from generic competition on Aubagio. Our strong results in the first six months make us confident in our outlook for the remainder of the year and as a consequence we are raising our full-year 2023 EPS guidance to mid single-digit growth.”